Unlocking STING as a Therapeutic Antiviral Strategy

Int J Mol Sci. 2023 Apr 18;24(8):7448. doi: 10.3390/ijms24087448.

Abstract

Invading pathogens have developed weapons that subvert physiological conditions to weaken the host and permit the spread of infection. Cells, on their side, have thus developed countermeasures to maintain cellular physiology and counteract pathogenesis. The cyclic GMP-AMP (cGAMP) synthase (cGAS) is a pattern recognition receptor that recognizes viral DNA present in the cytosol, activating the stimulator of interferon genes (STING) protein and leading to the production of type I interferons (IFN-I). Given its role in innate immunity activation, STING is considered an interesting and innovative target for the development of broad-spectrum antivirals. In this review, we discuss the function of STING; its modulation by the cellular stimuli; the molecular mechanisms developed by viruses, through which they escape this defense system; and the therapeutical strategies that have been developed to date to inhibit viral replication restoring STING functionality.

Keywords: STING; antivirals; innate immunity.

Publication types

  • Review

MeSH terms

  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • Immunity, Innate
  • Interferon Type I* / metabolism
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Nucleotidyltransferases / metabolism
  • Signal Transduction
  • Virus Replication

Substances

  • Antiviral Agents
  • Interferon Type I
  • Nucleotidyltransferases
  • Membrane Proteins